

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9939)

Clarification Announcement

Reference is made to the interim results announcement for the six months ended 30 June 2020 (the “**Announcement**”) of Kintor Pharmaceutical Limited (the “**Company**”) dated 21 August 2020. This clarification announcement is published for the purpose of clarifying a point in the Announcement.

Page 38 of the Announcement had a misstatement that “.....The Company’s principal place of business in Hong Kong has been changed to 40th Floor, Sunlight Tower, No. 248 Queen’s Road East, Wanchai, Hong Kong with effect from 21 August 2020.....”. The Company wishes to clarify that no change in the Company’s principal place of business in Hong Kong has been effected, and the Company’s principal place of business in Hong Kong remains at Suite 2007, 20th Floor Tower 2, The Gateway Harbour City Kowloon Hong Kong.

Except as stated above, all other information contained in the Announcement remains unchanged.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Executive Director

Hong Kong, 21 August 2020

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Dr. Chuangxing Guo, Mr. Gang Lu, Mr. Jie Chen, Dr. Bing Chen and Mr. Wei Zhang; and the independent non-executive Directors are Dr. Michael Min Xu, Dr. John Fenyu Jin and Mr. Wallace Wai Yim Yeung.

* *For identification purpose only*